Extra copy number of BCL2 is correlated with increased BCL-2 protein expression and poor survival in diffuse large B-cell lymphoma treated with chemoimmunotherapy

References

• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009;114(11):2273–2279.
   PubMed Web of Science ®Google Scholar
• Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the international DLBCL Rituximab-CHOP consortium program. Blood. 2013;121(20):4021–4031; quiz 4250.
   PubMed Web of Science ®Google Scholar
• Al-Juhaishi T, McKay J, Sindel A, et al. Perspectives on chemotherapy for the management of double-hit lymphoma. Expert Opin Pharmacother. 2020;21(6):653–661.
   PubMed Web of Science ®Google Scholar
• Riedell PA, Smith SM. Double hit and double expressors in lymphoma: definition and treatment. Cancer. 2018;124(24):4622–4632.
   PubMed Web of Science ®Google Scholar
• Huang S, Nong L, Wang W, et al. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma. Diagn Pathol. 2019;14(1):81.
   PubMedGoogle Scholar
• Krull JE, Wenzl K, Hartert KT, et al. Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients. Blood Cancer J. 2020;10(11):117.
   PubMed Web of Science ®Google Scholar
• Li S, Seegmiller AC, Lin P, et al. B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas. Mod Pathol. 2015;28(2):208–217.
   PubMed Web of Science ®Google Scholar
• Quesada AE, Medeiros LJ, Desai PA, et al. Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma. Mod Pathol. 2017;30(12):1688–1697.
   PubMed Web of Science ®Google Scholar
• Schieppati F, Balzarini P, Fisogni S, et al. An increase in MYC copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens. Haematologica. 2020;105(5):1369–1378.
   PubMed Web of Science ®Google Scholar
• Yoon SO, Jeon YK, Paik JH, et al. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal Centre-like B cell (GCB) type. Histopathology. 2008;53(2):205–217.
   PubMed Web of Science ®Google Scholar
• Ennishi D, Mottok A, Ben-Neriah S, et al. Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. Blood. 2017;129(20):2760–2770.
   PubMed Web of Science ®Google Scholar
• Sermer D, Bobillo S, Dogan A, et al. Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma. Blood Adv. 2020;4(14):3382–3390.
   PubMed Web of Science ®Google Scholar
• Hwang HS, Park CS, Yoon DH, et al. High concordance of gene expression profiling-correlated immunohistochemistry algorithms in diffuse large B-cell lymphoma, not otherwise specified. Am J Surg Pathol. 2014;38(8):1046–1057.
   PubMed Web of Science ®Google Scholar
• Hwang HS, Yoon DH, Hong JY, et al. The cell-of-origin classification of diffuse large B cell lymphoma in a Korean population by the Lymph2Cx assay and its correlation with immunohistochemical algorithms. Ann Hematol. 2018;97(12):2363–2372.
   PubMed Web of Science ®Google Scholar
• Roh J, Cho H, Pak HK, et al. BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis. Mod Pathol. 2022;35(4):480–488.
   PubMed Web of Science ®Google Scholar
• International Non-Hodgkin lymphoma prognostic factors P. A predictive model for aggressive non-Hodgkin lymphoma. N Engl J Med. 1993; Sep 30329(14):987–994.
   PubMed Web of Science ®Google Scholar
• Scott DW, Wright GW, Williams PM, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014;123(8):1214–1217.
   PubMed Web of Science ®Google Scholar
• Mazieres J, Brugger W, Cappuzzo F, et al. Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: re-analysis of the SATURN study. Lung Cancer. 2013;82(2):231–237.
   PubMed Web of Science ®Google Scholar
• McCarty KS, Jr., Miller LS, Cox EB, et al. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716–721.
   PubMed Web of Science ®Google Scholar
• Davis RE, Brown KD, Siebenlist U, et al. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001;194(12):1861–1874.
   PubMed Web of Science ®Google Scholar
• Zhang B, Calado DP, Wang Z, et al. An oncogenic role for alternative NF-kappaB signaling in DLBCL revealed upon deregulated BCL6 expression. Cell Rep. 2015;11(5):715–726.
   PubMed Web of Science ®Google Scholar
• Stasik CJ, Nitta H, Zhang W, et al. Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma. Haematologica. 2010;95(4):597–603.
   PubMed Web of Science ®Google Scholar
• Collinge B, Ben-Neriah S, Chong L, et al. The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC. Blood. 2021;137(16):2196–2208.
   PubMed Web of Science ®Google Scholar
• Copie-Bergman C, Cuilliere-Dartigues P, Baia M, et al. MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. Blood. 2015;126(22):2466–2474.
   PubMed Web of Science ®Google Scholar
• Pedersen MO, Gang AO, Poulsen TS, et al. MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations. Eur J Haematol. 2014;92(1):42–48.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Bens S, Advani R, et al. Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-Cell lymphoma: a study by the lunenburg lymphoma biomarker consortium. J Clin Oncol. 2019;37(35):3359–3368.
   PubMed Web of Science ®Google Scholar
• Tramm T, Kyndi M, Sorensen FB, et al. Influence of intra-tumoral heterogeneity on the evaluation of BCL2, E-cadherin, EGFR, EMMPRIN, and Ki-67 expression in tissue microarrays from breast cancer. Acta Oncol. 2018;57(1):102–106.
   PubMed Web of Science ®Google Scholar
• Chibon F, de Mascarel I, Sierankowski G, et al. Prediction of HER2 gene status in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations. Mod Pathol. 2009;22(3):403–409.
   PubMed Web of Science ®Google Scholar